products - Integrated DNA Technologies

INTEGRATEDDNATECHNOLOGIESPRODUCTSSTANDARD TERMS & CONDITIONS OF SALENotice: The 5’ Nuclease Assay and other homogenous amplification methods used in connection with the Polymerase Chain Reaction(“PCR”) process are covered by patents owned by Roche Molecular Systems, Inc. and F. Hoffman La-Roche Ltd (“Roche”). No license to use the5’ Nuclease Assay or any Roche patented homogenous amplification process is conveyed expressly or by implication to the purchaser by thepurchase of the above listed products or any other IDT products. Additionally, no license to use methods covered by Genetic TechnologiesLimited (GTG) patents relating to allelic discrimination or SNP genotyping are conveyed by the purchase of IDT oligonucleotides.Gene KnockdownRNAi. IDT’s products are licensed under U.S. and international patent rights owned by the Carnegie Institution of Washington thatcover RNA interference. These products are accompanied by a limited non-exclusive worldwide license under the Carnegie Institutionof Washington’s patent rights for researchers at academic or other not-for-profit institutions to use the products for non-profit research.However, use of dsRNA for RNA interference by for-profit organizations requires a license from the Carnegie Institution of Washington.siRNA. This product is licensed under European Patents 1144623, 121945 and foreign equivalents from Alnylam Pharmaceuticals,Inc., Cambridge, USA and is provided only for use in academic and commercial research whose purpose is to elucidate gene function,including research to validate potential gene products and pathways for drug discovery and development and to screen non-siRNA basedcompounds (but excluding the evaluation or characterization of this product as the potential basis for an siRNA-based drug) and not for anyother commercial purposes. Information about licenses for commercial use (including discovery and development of siRNA-based drugs) isavailable from Alnylam Pharmaceuticals, Inc., 300 Third Street, Cambridge MA 02142, USA.DsiRNA and TriFECTa are trademarks of IDT. IDT is exclusively licensed under patents owned by the City of Hope and IDT to make andsell DsiRNA products for use in research and development. Use of DsiRNA products or technology in humans or for human or veterinarydiagnostic, prophylactic or therapeutic purposes requires a separate license from City of Hope Medical Center.Chimeric Antisense Oligos. In addition to an exclusive license under University of Iowa Research Foundation patents, IDT is the soleoligonucleotide supplier licensed under several patents owned or presently controlled by ISIS Pharmaceuticals, Inc. to manufacture and sellChimeric Antisense Oligonucleotides to universities and other non-profit institutions for research purposes. Certain design, sequence, scaleand use restrictions may apply. IDT reserves the unlimited right to refuse any order for Chimeric Antisense Oligos.DNA-Directed RNAi. Use of IDT oligos for DNA-Directed RNAi research is protected by patents co-owned by Benitec Australia Ltd., andlicensed exclusively to Promega Corporation in the human field (excluding human therapeutics). For information regarding licensing ofddRNAi technology, please visit www.promega.com/licensing. For licensing any human therapeutic purpose, contact Benitec Australia Ltdat info@benitec.com.Locked Nucleic Acids (LNAs). IDT is licensed under patents and patent applications assigned to Exiqon A/S to sell oligonucleotidesincorporating LNAs for research purposes only. Resale of LNA-oligos and their use in humans or in therapeutic applications are allprohibited.TriFECTin is a trademark of IDT.Other LicensesAcrydite. IDT is licensed under U.S. Patent Number 6,180,770, and 5,932,711 to sell oligos incorporating Acrydite modifications foruse solely in the purchaser’s own life sciences research and development activities. Resale, or use of this product in clinical or diagnosticapplications, or other commercial applications, requires separate license from Matrix Technologies, Inc. Acrydite is a trademark of MatrixTechnologies, Inc.Digoxigenin is licensed by Roche Diagnostics GmbH. The use of digoxigenin technology to label nucleic acids is licensed under patents (EP0 324 474, US 5,344,757, US 5,702,888, US 5,354,657, JP 1999884 and HK 1169) owned by Roche Diagnostics GmbH. For further informationon products to label and detect digoxigenin-modified nucleic acids refer to www.rocheapplied-science.com/dig/Iso dC and Iso dG and Plexor. IDT is licensed by EraGen Biosciences, Inc., under U.S. Patent Numbers 5,432,272; 6,001,983; 6,037,120; and6,140,496, and other pending applications to sell oligonucleotides for non-commercial, research use in the life sciences research market.Plexor is a trademark of Promega Corporation.RNaseAlert compositions and methods are protected under U.S. Patent No. 6,773,885 and other pending IDT patent(s). RNaseAlert is atrademark of Ambion, Inc.Rapid HPLC, Express DLP, SameDay®, HotPlates, Ultramer, miniGenes, miRFire , ReadyMade Primers, OligoCard,I-Linker and DNaseAlert are trademarks of Integrated DNA Technologies, Inc.StarFire® is a registered trademark of IDT, and its compositions and methods are protected under pending IDT patent(s).SAGE is a trademark of Genzyme Molecular Oncology. Purchase of IDT oligos does not confer to customer a license to perform SAGEmethods. For more information, contact Genzyme or Johns Hopkins University.Uni-Link is a trademark of Clontech Laboratories, Inc.©2008 Integrated DNA Technologies www.idtdna.com83